WallStSmart

Insmed Inc (INSM)vsSatellos Bioscience Inc. Common Stock (MSLE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MSLE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

MSLE

Avoid

18

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for INSM.

MSLEUndervalued (+33.4%)

Margin of Safety

+33.4%

Fair Value

$17.48

Current Price

$7.12

$10.36 discount

UndervaluedFair: $17.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

MSLE1 strengths · Avg: 10.0/10
P/E RatioValuation
2.9x10/10

Attractively priced relative to earnings

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

MSLE4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$152.45M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : MSLE

The strongest argument for MSLE centers on P/E Ratio.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : MSLE

The primary concerns for MSLE are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while MSLE is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

MSLE generates stronger free cash flow (-4M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 18/100). MSLE offers better value entry with a 33.4% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Satellos Bioscience Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company is headquartered in Toronto, Canada.

Want to dig deeper into these stocks?